A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age
Фаза 3
Завершено
NCT06060457
| Заболевание | Respiratory Syncytial Virus |
|---|
| Фаза | Фаза 3 |
|---|
| Спонсор | ModernaTX, Inc. |
|---|
| Статус | Завершено |
|---|
| Участники | 1,900 участн. |
|---|
| Вмешательство | mRNA-1345, Fluzone HD |
|---|
| Дата начала | 25.09.2023 |
|---|
| Дата завершения | 7.06.2024 |
|---|
| Публикация результатов | 30.07.2025 |
|---|
Кратко
The main purpose of this study is to evaluate the safety and immunogenicity of mRNA-1345 RSV vaccine when coadministered with a high dose (HD) quadrivalent seasonal influenza vaccine (Fluzone HD) in adults ≥65 years of age. The study will examine the impact of Fluzone HD on the immune response to mRNA-1345 against RSV-A and RSV-B, as well as the impact of mRNA-1345 on the immune response to Fluzone HD against 4 vaccine-matched Influenza A and B strains.
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection
Within 7 days after Day 1 injection · Participants
| Fluzone HD + mRNA-1345 Followed by Placebo | 689 Participants |
|---|
| Fluzone HD + Placebo Followed by mRNA-1345 | 547 Participants |
|---|
Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 22 Injection
Within 7 days after Day 22 injection · Participants
| Fluzone HD + mRNA-1345 Followed by Placebo | 251 Participants |
|---|
| Fluzone HD + Placebo Followed by mRNA-1345 | 557 Participants |
|---|
Number of Participants With Unsolicited Adverse Events (AEs) Up to 21 Days After Day 1 Injection
Up to 21 days after Day 1 injection · Participants
| Fluzone HD + mRNA-1345 Followed by Placebo | 72 Participants |
|---|
| Fluzone HD + Placebo Followed by mRNA-1345 | 72 Participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.